Q2 Earnings Forecast for Zymeworks Issued By Lifesci Capital

Zymeworks Inc. (NASDAQ:ZYME) – Equities researchers at Lifesci Capital dropped their Q2 2026 EPS estimates for Zymeworks in a note issued to investors on Thursday, May 7th. Lifesci Capital analyst C. Zhu now expects that the company will post earnings per share of ($0.58) for the quarter, down from their previous forecast of ($0.49). The consensus estimate for Zymeworks’ current full-year earnings is $0.97 per share. Lifesci Capital also issued estimates for Zymeworks’ Q3 2026 earnings at $2.68 EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at $0.88 EPS and FY2027 earnings at ($0.91) EPS.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.59) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million for the quarter. Zymeworks had a negative net margin of 126.92% and a negative return on equity of 37.97%.

Several other equities analysts also recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. HC Wainwright raised their price target on shares of Zymeworks from $32.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research note on Monday, April 20th. Wells Fargo & Company raised their price target on shares of Zymeworks from $33.00 to $34.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Leerink Partners raised their price target on shares of Zymeworks from $52.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.00.

Zymeworks Trading Up 0.6%

NASDAQ:ZYME opened at $24.03 on Tuesday. The company’s 50-day moving average price is $25.62 and its 200-day moving average price is $24.14. The company has a market cap of $1.75 billion, a P/E ratio of -17.54 and a beta of 1.20. Zymeworks has a twelve month low of $10.93 and a twelve month high of $29.75.

Institutional Investors Weigh In On Zymeworks

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Zymeworks in the 4th quarter valued at approximately $2,338,000. Capricorn Fund Managers Ltd purchased a new stake in shares of Zymeworks in the 4th quarter valued at approximately $26,931,000. Pictet Asset Management Holding SA purchased a new stake in shares of Zymeworks in the 4th quarter valued at approximately $1,966,000. Vanguard Group Inc. raised its stake in shares of Zymeworks by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company’s stock valued at $61,315,000 after acquiring an additional 174,293 shares during the period. Finally, Apollon Wealth Management LLC purchased a new stake in shares of Zymeworks in the 4th quarter valued at approximately $207,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.